The Technical Analyst
Illumina Inc [ILMN]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Illumina Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.50% $124.46
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 19 777 mill |
| EPS: | -7.34 |
| P/E: | -16.96 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 158.90 mill |
| Avg Daily Volume: | 1.683 mill |
| RATING 2024-04-23 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -16.96 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.91x |
| Company: PE -16.96 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$53.28 (-57.19%) $-71.18 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 119.44 - 129.48 ( +/- 4.03%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Rollins Carissa | Sell | 122 | Common Stock |
| 2024-03-28 | Ullem Scott B. | Buy | 163 | Common Stock |
| 2024-03-05 | Leckman Patricia | Buy | 7 054 | Common Stock |
| 2024-03-05 | Leckman Patricia | Buy | 5 755 | Performance Shares |
| 2024-03-03 | Leckman Patricia | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 83.36 |
| Last 99 transactions |
| Buy: 313 821 | Sell: 32 606 |
Forecast:
16:00 - $124.28
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $124.28
Forecast 2: 16:00 - $124.28
Forecast 3: 16:00 - $124.28
SCORE
-8.00
Sell
-8.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $124.46 (3.50% ) |
| Volume | 1.302 mill |
| Avg. Vol. | 1.683 mill |
| % of Avg. Vol | 77.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ILMN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $143.59 | N/A | Active |
|---|
ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Latest Press Releases
2024-04-12 09:00:00 - Press Release
Illumina's Planned Divestment Of Grail Approved By The European Commission
San diego , april 12, 2024 /prnewswire/ -- illumina, inc. (nasdaq: ilmn), a global leader in dna sequencing and array-based technologies, today announced it has received approval of its divestment plan for grail from the european commission (ec). while this does not mean the method of divestment has been finalized, the company is pleased to reach an agreement with the ec on specific divestment options as it represents an important milestone in the process.
2024-04-09 16:05:00 - Press Release
Illumina Appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy And Corporate Development Officer
Joydeep goswami to serve as advisor through june 30 illumina reaffirms q1 2024 and full-year 2024 financial guidance san diego , april 9, 2024 /prnewswire/ -- illumina, inc. (nasdaq: ilmn), a global leader in dna sequencing and array-based technologies, today announced that joydeep goswami has decided to leave illumina. he will stay on in an advisory role through june 30 to support two new executive management team appointments.
2024-04-04 17:00:00 - Press Release
Illumina To Announce First Quarter 2024 Financial Results On Thursday, May 2, 2024
San diego , april 4, 2024 /prnewswire/ -- illumina, inc. (nasdaq: ilmn) announced today that it will issue results for the first quarter 2024 following the close of market on thursday, may 2, 2024. on the same day, at 2:00 pm pacific time (5:00 pm eastern time) jacob thaysen, chief executive officer, and joydeep goswami, chief financial officer and chief strategy and corporate development officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
2024-02-08 16:05:00 - Press Release
Illumina Reports Financial Results For Fourth Quarter And Fiscal Year 2023
Revenue of $1.12 billion for q4 2023, up 4% from q4 2022 (up 4% on a constant currency basis) revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) shipped 79 novaseq x instruments in q4 2023 and 352 instruments for fiscal year 2023 gaap diluted loss per share of $(1.11) for q4 2023, compared to gaap diluted loss per share of $(0.89) for q4 2022 non-gaap diluted earnings per share of $0.14 for both q4 2023 and q4 2022 gaap diluted loss per share of $(7.34) for fiscal year 2023, which included goodwill and intangible impairments of $821 million related to the grail segment, compared to gaap diluted loss per share of $(28.00) for fiscal year 2022, which included goodwill impairment of $3...
2024-01-15 07:00:00 - Press Release
Concentric By Ginkgo And Illumina Collaborate To Deploy Biosurveillance Technologies Around The World
The companies plan to join forces to set up pathogen monitoring programs utilizing illumina technology across concentric's global network boston and san diego , jan. 15, 2024 /prnewswire/ -- concentric by ginkgo, the biosecurity and public health unit of ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a co-marketing agreement with illumina, inc. (nasdaq: ilmn), a global leader in dna sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally. concentric is building a global pathogen monitoring network—a "bioradar" system —in countries around the world to detect, characterize, and rapidly respond to biological threats and help drive informed decision-making in support of global health objectives.
Latest News
2024-04-19 13:15:30 - Zacks Investment Research
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2024-04-16 11:50:02 - Morningstar
2 Cheap Growth Stocks to Buy During 2Q
These undervalued stocks from the growth side of the Morningstar style box are among our analysts' favorites today. 00:00 Introduction 00: 31 Adobe ADBE 01:09 Illumina ILMN I'm Susan Dziubinski with Morningstar.
2024-04-12 05:50:18 - Reuters
EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
2024-04-09 16:33:00 - Reuters
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
2024-04-05 14:27:56 - InvestorPlace
Nasdaq's Nosebleed Section: 3 Expensive Stocks to Sell Before It's Too Late
The stock market has been in a solid rally since the third quarter of 2023, pushing significant indices to new highs. That upward trajectory also raised company valuations for many stocks, putting investors at risk of inflated stock prices and selloffs.
2024-04-04 17:00:00 - PRNewsWire
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
SAN DIEGO , April 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the first quarter 2024 following the close of market on Thursday, May 2, 2024. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
2024-03-26 09:56:16 - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
2024-03-21 18:37:13 - The Motley Fool
Why Illumina Stock Zoomed Higher on Thursday
The gene-sequencing specialist might be able to complete a big-ticket asset buy after all. Its attempt to purchase Grail for $8 billion had been blocked by a European Union regulator.
2024-03-21 05:12:16 - Reuters
EU court should back Illumina's appeal against EU review of Grail deal, court adviser says
Europe's top court should back U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1 billion bid for cancer test maker Grail , an adviser to the court said on Thursday.
2024-03-12 13:57:32 - Reuters
Exclusive: Icahn drops Illumina board challenge threat, sources say
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina's board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, according to people familiar with the matter.